Cart summary

You have no items in your shopping cart.

5-Fluorouracil

SKU: orb1310103

Description

5-Fluorouracil (5-FU) is a pyrimidine analog and potent thymidylate synthase inhibitor, disrupting DNA synthesis to induce apoptosis and autophagy. It is widely used in cancer research for both in vitro cell studies and in vivo tumor model experiments.

Research Area

Cell Biology, Infectious Disease & Virology, Metabolism Research, Molecular Biology, Protein Biochemistry

Images & Validation

Key Properties

CAS Number51-21-8
MW130.08
Purity99.83%
FormulaC4H3FN2O2
SMILESFC1=CNC(=O)NC1=O
TargetNucleoside Antimetabolite/Analog,DNA/RNA Synthesis,HIV Protease,Endogenous Metabolite,Apoptosis
SolubilityDMSO:92 mg/mL (707.26 mM);H2O:10 mg/mL (76.8 mM);10% DMSO+90% Saline:1.31 mg/mL (10.07 mM);Ethanol:1.31 mg/mL (10.07 mM)

Bioactivity

Target IC50
TE-15 cells proliferation:39.81 μM|CWH22 organoids:3.3 μM|TE-12 cells proliferation:2.95 μM|CLM22 organoids:3.78 μM|TE-3 cells proliferation:4.37 μM|KYSE30 cells proliferation:3.89 μM|TE-8 cells proliferation:1 μM|TE-1 cells proliferation:27.54 μM|KYSE410 cells proliferation:8.51 μM
In Vivo
METHODS: To detect the antitumor activity in vivo, 5-Fluorouracil (10-40 mg/kg) was injected intraperitoneally once a day for ten days into mice bearing ascites hepatocellular carcinoma tumor H22. RESULTS: 5-Fluorouracil at 10 mg/kg inhibited tumor growth while maintaining immune function in mice. 5-Fluorouracil exerts low-dose, low-toxicity antitumor effects and stimulates the host immune system. METHODS: To study 5-Fluorouracil-induced intestinal injury, 5-Fluorouracil (100-200 mg/kg) was administered as a single intraperitoneal injection to BALB/c mice. RESULTS: The body weight and diarrhea symptoms of 5-Fluorouracil-treated animals were significantly reduced in a dose-dependent manner. Occludin and claudin-1 protein expression was significantly reduced in the 5-Fluorouracil-treated group. 5-Fluorouracil-treated group showed significantly higher NF-κBp65 protein and TNF-α mRNA expression than the control group. NF-κBp65 protein and TNF-α mRNA expression were significantly higher in the 5-Fluorouracil treated group than in the control group.
In Vitro
METHODS: Human cardiomyocytes HCM, human umbilical vein endothelial cells HUVE, and human colon cancer cells HCT116 and HT29 were treated with 5-Fluorouracil (0.01-1000 µM) for 24-96 h, and the growth inhibition of the cells was detected by MTT. RESULTS: The EC50 of 5-Fluorouracil on HCM, HUVE, PHCT116 and HT29 cells were 4.866 μM, 3.832 μM, 13.72 μM and 106.8 μM, respectively, at 72 h. METHODS: Smooth muscle cells were treated with 5-Fluorouracil (0.05-10 mM) for 24 h. Apoptosis was detected using Flow Cytometry. RESULTS: 5-Fluorouracil at concentrations of 0.1, 1, and 10 mM induced apoptosis in cultured smooth muscle cells after 24 h of treatment, and the apoptotic cells were detached from the culture dishes. METHODS: Human colon cancer cells SW620 were incubated with 5-Fluorouracil (13 μg/mL) for 24-48 h. ALP activity was detected using an ALP detection kit. RESULTS: Alkaline phosphatase (ALP) has been used to monitor the differentiation effects of certain anticancer compounds. Untreated SW620 cells showed relatively low ALP activity, while in cells treated with 13 μg/ml 5-FU, ALP activity reached high levels in a time-dependent manner.
Cell Research
After a 7-day habituation period, the mice were divided into three groups (vehicle group, dextrin group, and ED group; n = 6 mice per group) that had the same mean body weight (time of grouping was designated as day 0). Then, mice were treated by tail vein injections from day 0 to 4; mice in the dextrin and ED groups received 40 mg/kg/day of 5- fluorouracil (5-FU) injection 250 mg, while mice in the vehicle group received 10 mL/kg/day physiological saline, which was equivalent to the dose of 5-FU. Additionally, twice a day from day 0 to 6, ED group mice received 1.6 kcal/0.8 mL/day ED administered orally, while mice in the vehicle and dextrin groups received dextrin containing the same amount of calories. Body weight and food consumption were measured before administration of 5-FU and ED on days 0 and 7. Food consumption was measured with respect to each group. Mice were accommodated individually in specially prepared polycarbonate cages, and two or more fresh stools per mouse were scored as follows: 0, the stools were not crushed when pushed by human fingers; 1, the stools were crushed, but the core remained when pushed by human fingers; 2, the stools were crushed and the core did not remain when pushed by human fingers; 3, the stools were crushed and stuck to the fingers when pushed by human fingers; 4, the stools lost their shape just from being touched. Autopsies were conducted on day 7. After bleeding, the large intestine (the colon and rectum) was taken, and the length was measured. The lumen was washed with physiological saline, the excess water was wiped off, and specimens were weighed. Section 3 cm distal from the center of the large intestine was fixed with formalin for histological evaluation. Salivary glands (the submandibular gland and sublingual gland) were collected and weighed. The collected salivary glands were fixed with formalin, and after the tissue sections were prepared, they were stained with hematoxylin and eosin .

Storage & Handling

StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

RNA Synthesis, RNASynthesis, Thymidylate synthase, inhibit, NSC 19893, NSC19893, NSC-19893, Nucleoside Antimetabolite/Analog, Nucleoside Antimetabolite, NucleosideAntimetabolite, Fluorouracil, Endogenous Metabolite, EndogenousMetabolite, Inhibitor, Human immunodeficiency virus, HIV Protease, HIV, HIVProtease, DNA Synthesis, DNASynthesis, Analog, Apoptosis, 5 Fluorouracil, 5-FU, 5-Fluorouracil, 5Fluorouracil, 5-Fluoracil

Similar Products

  • TYMS Antibody / Thymidylate Synthase [orb2640443]

    FACS,  IF,  IHC-P,  WB

    Human

    Mouse

    Monoclonal

    Unconjugated

    100 μg
  • TYMS Antibody / Thymidylate Synthase [orb606355]

    FACS,  IF,  IHC-P,  WB

    Human

    Mouse

    Monoclonal

    Unconjugated

    100 μg, 20 μg
  • Rabbit MBD4 Antibody [orb1528053]

    IHC,  IP,  WB

    Human

    Rabbit

    Polyclonal

    Unconjugated

    100 μl, 10 μl
  • Recombinant Thymidylate Synthase Antibody / TYMS [orb2636350]

    IHC-P

    Human

    Rabbit

    Recombinant

    Unconjugated

    100 μg
  • Recombinant Thymidylate Synthase Antibody / TYMS [orb2636351]

    IHC-P

    Human

    Rabbit

    Recombinant

    Unconjugated

    100 μg, 20 μg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Key Properties

No computed properties available.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

5-Fluorouracil (orb1310103)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

250 mg
$ 130.00
1 g
$ 150.00
DispatchUsually dispatched within 3-5 working days
Bulk Enquiry